You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDextroamphetamine
Accession NumberDB01576
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionDextroamphetamine is the dextrorotary stereoisomer of the amphetamine molecule, which can take two different forms. It is a slightly polar, weak base and is lipophilic.
Structure
Thumb
Synonyms
(+)-(S)-amphetamine
(+)-alpha-Methylphenethylamine
(+)-alpha-Methylphenylethylamine
(+)-Amphetamine
(AlphaS)-alpha-methylbenzeneethanamine
(S)-(+)-Amphetamine
(S)-(+)-beta-Phenylisopropylamine
(S)-1-Phenyl-2-aminopropane
(S)-1-Phenyl-2-propylamine
(S)-alpha-Methylbenzeneethanamine
(S)-amphetamine
d-amphetamine
Dexamfetamine
dexamphetamine
Dextroamphetamine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Dextroamphetamine SRCapsule, extended release10 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
Act Dextroamphetamine SRCapsule, extended release15 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
Dexedrine SpansuleCapsule, extended release5 mg/1OralAmedra Pharmaceuticals LLC1976-08-02Not applicableUs
Dexedrine SpansuleCapsule, extended release10 mg/1OralAmedra Pharmaceuticals LLC1976-08-02Not applicableUs
Dexedrine SpansuleCapsule, extended release15 mg/1OralAmedra Pharmaceuticals LLC1976-08-02Not applicableUs
Dexedrine Spansule Src 10mgCapsule, extended release10 mgOralPaladin Labs Inc1992-12-31Not applicableCanada
Dexedrine Spansule Src 15mgCapsule, extended release15 mgOralPaladin Labs Inc1992-12-31Not applicableCanada
Dexedrine Tablets (5mg)Tablet5 mgOralPaladin Labs Inc1992-12-31Not applicableCanada
Dextroamphetamine Sulfate Extended-releaseCapsule, extended release10 mg/1OralLineage Therapeutics1976-08-02Not applicableUs
Dextroamphetamine Sulfate Extended-releaseCapsule, extended release15 mg/1OralLineage Therapeutics1976-08-02Not applicableUs
Dextroamphetamine Sulfate Extended-releaseCapsule, extended release5 mg/1OralLineage Therapeutics1976-08-02Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-dextroamphetamineTablet5 mgOralApotex Inc2015-08-28Not applicableCanada
DexedrineTablet5 mg/1OralAmedra Pharmaceuticals LLC2014-07-01Not applicableUs
DexedrineTablet10 mg/1OralAmedra Pharmaceuticals LLC2014-07-01Not applicableUs
DextroamphetamineSolution5 mg/5mLOralTris Pharma Inc2013-05-31Not applicableUs
Dextroamphetamine SulfateTablet7.5 mg/1OralMikart, Inc.2011-10-25Not applicableUs
Dextroamphetamine SulfateTablet10 mg/1OralCore Pharma, Llc2014-05-15Not applicableUs
Dextroamphetamine SulfateTablet10 mg/1OralGAVIS Pharmaceuticals, LLC2016-04-25Not applicableUs
Dextroamphetamine SulfateTablet10 mg/1OralKvk Tech, Inc.2015-11-23Not applicableUs
Dextroamphetamine SulfateCapsule, extended release10 mg/1OralPhysicians Total Care, Inc.2005-11-30Not applicableUs
Dextroamphetamine SulfateTablet10 mg/1OralMallinckrodt, Inc.2010-02-05Not applicableUs
Dextroamphetamine SulfateCapsule, extended release10 mg/1OralActavis Pharma, Inc.2014-06-19Not applicableUs
Dextroamphetamine SulfateTablet5 mg/1OralTeva Pharmaceuticals Usa, Inc.2001-02-12Not applicableUs
Dextroamphetamine SulfateTablet30 mg/1OralMikart, Inc.2011-10-25Not applicableUs
Dextroamphetamine SulfateTablet5 mg/1OralZydus Pharmaceuticals (USA) Inc.2016-03-28Not applicableUs
Dextroamphetamine SulfateCapsule, extended release10 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
Dextroamphetamine SulfateTablet5 mg/1OralNovel Laboratories, Inc.2016-03-16Not applicableUs
Dextroamphetamine SulfateCapsule, extended release10 mg/1OralBarr Laboratories Inc.2002-02-26Not applicableUs
Dextroamphetamine SulfateTablet5 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-07Not applicableUs
Dextroamphetamine SulfateTablet5 mg/1OralAurolife Pharma, LLC2012-02-14Not applicableUs
Dextroamphetamine SulfateTablet10 mg/1OralMikart, Inc.2011-10-25Not applicableUs
Dextroamphetamine SulfateSolution5 mg/5mLOralTalec Pharma, LLC2014-01-06Not applicableUs
Dextroamphetamine SulfateCapsule, extended release5 mg/1OralMayne Pharma Inc.2016-08-05Not applicableUs
Dextroamphetamine SulfateTablet5 mg/1OralEthex Corporation2009-11-01Not applicableUs
Dextroamphetamine SulfateCapsule, extended release5 mg/1OralMylan Pharmaceuticals Inc.2016-07-20Not applicableUs
Dextroamphetamine SulfateCapsule, extended release15 mg/1OralActavis Pharma, Inc.2014-06-19Not applicableUs
Dextroamphetamine SulfateTablet10 mg/1OralZydus Pharmaceuticals (USA) Inc.2016-03-28Not applicableUs
Dextroamphetamine SulfateTablet10 mg/1OralTeva Pharmaceuticals Usa, Inc.2001-02-12Not applicableUs
Dextroamphetamine SulfateTablet2.5 mg/1OralMikart, Inc.2011-10-25Not applicableUs
Dextroamphetamine SulfateTablet10 mg/1OralNovel Laboratories, Inc.2016-03-16Not applicableUs
Dextroamphetamine SulfateCapsule, extended release15 mg/1OralBarr Laboratories Inc.2002-02-26Not applicableUs
Dextroamphetamine SulfateTablet10 mg/1OralAurolife Pharma, LLC2012-02-14Not applicableUs
Dextroamphetamine SulfateTablet15 mg/1OralMikart, Inc.2011-10-25Not applicableUs
Dextroamphetamine SulfateTablet5 mg/1OralWilshire Pharmaceuticals, Inc.2012-07-16Not applicableUs
Dextroamphetamine SulfateCapsule, extended release10 mg/1OralMayne Pharma Inc.2016-08-05Not applicableUs
Dextroamphetamine SulfateTablet10 mg/1OralEthex Corporation2009-11-01Not applicableUs
Dextroamphetamine SulfateCapsule, extended release10 mg/1OralMylan Pharmaceuticals Inc.2016-07-20Not applicableUs
Dextroamphetamine SulfateSolution5 mg/5mLOralMikart, Inc.2008-01-29Not applicableUs
Dextroamphetamine SulfateTablet5 mg/1OralMikart, Inc.2011-10-25Not applicableUs
Dextroamphetamine SulfateTablet5 mg/1OralCore Pharma, Llc2014-05-15Not applicableUs
Dextroamphetamine SulfateTablet5 mg/1OralGAVIS Pharmaceuticals, LLC2016-04-25Not applicableUs
Dextroamphetamine SulfateTablet5 mg/1OralKvk Tech, Inc.2015-11-23Not applicableUs
Dextroamphetamine SulfateTablet20 mg/1OralMikart, Inc.2011-10-25Not applicableUs
Dextroamphetamine SulfateTablet10 mg/1OralWilshire Pharmaceuticals, Inc.2012-07-20Not applicableUs
Dextroamphetamine SulfateCapsule, extended release15 mg/1OralMayne Pharma Inc.2016-08-05Not applicableUs
Dextroamphetamine SulfateCapsule, extended release5 mg/1OralBarr Laboratories Inc.2002-02-26Not applicableUs
Dextroamphetamine SulfateTablet10 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
Dextroamphetamine SulfateCapsule, extended release15 mg/1OralMylan Pharmaceuticals Inc.2016-07-20Not applicableUs
Dextroamphetamine SulfateCapsule, extended release15 mg/1OralPhysicians Total Care, Inc.2005-08-15Not applicableUs
Dextroamphetamine SulfateTablet5 mg/1OralMallinckrodt, Inc.2010-02-05Not applicableUs
Dextroamphetamine SulfateCapsule, extended release5 mg/1OralActavis Pharma, Inc.2014-06-19Not applicableUs
Dextroamphetamine Sulfate Extended-releaseCapsule, extended release5 mg/1OralMallinckrodt, Inc.2011-10-07Not applicableUs
Dextroamphetamine Sulfate Extended-releaseCapsule, extended release10 mg/1OralMallinckrodt, Inc.2011-10-07Not applicableUs
Dextroamphetamine Sulfate Extended-releaseCapsule, extended release15 mg/1OralAmerican Health Packaging2015-06-01Not applicableUs
Dextroamphetamine Sulfate Extended-releaseCapsule, extended release15 mg/1OralMallinckrodt, Inc.2011-10-07Not applicableUs
ProcentraSolution5 mg/5mLOralIndependence Pharmaceuticals, LLC2014-05-15Not applicableUs
ProcentraLiquid5 mg/5mLOralFSC Laboratories, Inc2010-08-01Not applicableUs
ZenzediTablet10 mg/1OralArbor Pharmaceuticals, Inc.2013-05-31Not applicableUs
ZenzediTablet15 mg/1OralArbor Pharmaceuticals, Inc.2014-05-01Not applicableUs
ZenzediTablet2.5 mg/1OralArbor Pharmaceuticals, Inc.2013-05-31Not applicableUs
ZenzediTablet20 mg/1OralArbor Pharmaceuticals, Inc.2014-05-01Not applicableUs
ZenzediTablet5 mg/1OralArbor Pharmaceuticals, Inc.2013-05-31Not applicableUs
ZenzediTablet30 mg/1OralArbor Pharmaceuticals, Inc.2014-05-01Not applicableUs
ZenzediTablet7.5 mg/1OralArbor Pharmaceuticals, Inc.2013-05-31Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AttentinMedice
DexamphetamineSigma
Brand mixtures
NameLabellerIngredients
Act Amphetamine XRActavis Pharma Company
Adderallbryant ranch prepack
Adderall XRShire US Manufacturing Inc.
Apo-amphetamine XRApotex Inc
Dextroamphetamine Saccharate and Amphetamine Aspartate and Dextroamphetamine Sulfate and Amphetamine SulfateMallinckrodt, Inc.
Dextroamphetamine Saccharate, Amphetamine Aspartate (monohydrate), Dextroamphetamine Sulfate, Amphetamine SulfateMylan Pharmaceuticals Inc.
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine SulfateEon Labs, Inc.
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine SulfateActavis Pharma, Inc.
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine SuflateSTAT Rx USA LLC
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine SulfateGlobal Pharmaceuticals, Division of Impax Laboratories Inc.
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine SulfateBarr Laboratories Inc.
PMS-amphetamines XRPharmascience Inc
Sandoz Amphetamine XRSandoz Canada Incorporated
Salts
Name/CASStructureProperties
Dextroamphetamine adipate
ThumbNot applicableDBSALT001324
Dextroamphetamine saccharate
ThumbNot applicableDBSALT001346
Dextroamphetamine sulfate
Thumb
  • InChI Key: SOFQDLYSFOWTJX-QRPNPIFTSA-N
  • Monoisotopic Mass: 233.072178663
  • Average Mass: 233.285
DBSALT000046
Categories
UNIITZ47U051FI
CAS number51-64-9
WeightAverage: 135.2062
Monoisotopic: 135.104799421
Chemical FormulaC9H13N
InChI KeyKWTSXDURSIMDCE-QMMMGPOBSA-N
InChI
InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1
IUPAC Name
(2S)-1-phenylpropan-2-amine
SMILES
C[[email protected]](N)CC1=CC=CC=C1
Pharmacology
IndicationUsed to treat attention deficit hyperactivity disorder (ADHD).
Structured Indications
PharmacodynamicsAmphetamines such as dextroamphetamine are noncatecholamine, sympathomimetic amines with CNS stimulant activity. Peripheral actions include elevations of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action. There is neither specific evidence that clearly establishes the mechanism whereby amphetamines produce mental and behavioral effects in children, nor conclusive evidence regarding how these effects relate to the condition of the central nervous system.
Mechanism of actionThe exact mechanism of action is not known. Dextroamphetamine stimulates the release of norepinephrine from central adrenergic receptors. At higher dosages, it causes release of dopamine from the mesocorticolimbic system and the nigrostriatal dopamine systems by reversal of the monoamine transporters. Dextroamphetamine may also act as a direct agonist on central 5-HT receptors and may inhibit monoamine oxidase (MAO). In the periphery, amphetamines are believed to cause the release of noradrenaline by acting on the adrenergic nerve terminals and alpha- and beta-receptors. Modulation of serotonergic pathways may contribute to the calming affect.
TargetKindPharmacological actionActionsOrganismUniProt ID
Synaptic vesicular amine transporterProteinyes
inducer
HumanQ05940 details
Sodium-dependent noradrenaline transporterProteinyes
negative modulator
HumanP23975 details
Sodium-dependent dopamine transporterProteinyes
negative modulator
HumanQ01959 details
Trace amine-associated receptor 1Proteinunknown
agonist
HumanQ96RJ0 details
Alpha-1A adrenergic receptorProteinunknownNot AvailableHumanP35348 details
Alpha-1B adrenergic receptorProteinunknown
antagonist
HumanP35368 details
Related Articles
AbsorptionOral bioavailability is over 75%.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half life10-28 hours (average is approximately 12 hours)
ClearanceNot Available
ToxicityIn rats, the oral LD50 of dextroamphetamine sulfate is 96.8 mg/kg. Manifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rhabdomyolysis, rapid respiration, hyperpyrexia, confusion, assaultiveness, hallucinations, panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmias, hypertension or hypotension, and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning is usually preceded by convulsions and coma.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypertensive activities of Dextroamphetamine.Experimental
AbirateroneThe serum concentration of Dextroamphetamine can be increased when it is combined with Abiraterone.Approved
AcepromazineAcepromazine may decrease the stimulatory activities of Dextroamphetamine.Approved, Vet Approved
AceprometazineAceprometazine may decrease the stimulatory activities of Dextroamphetamine.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved, Vet Approved
AcetophenazineAcetophenazine may decrease the stimulatory activities of Dextroamphetamine.Approved
AcrivastineDextroamphetamine may decrease the sedative activities of Acrivastine.Approved
AlcaftadineDextroamphetamine may decrease the sedative activities of Alcaftadine.Approved
AlfentanilDextroamphetamine may increase the analgesic activities of Alfentanil.Approved, Illicit
AlimemazineDextroamphetamine may decrease the sedative activities of Alimemazine.Approved, Vet Approved
AlphacetylmethadolDextroamphetamine may increase the analgesic activities of Alphacetylmethadol.Experimental, Illicit
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved
Aluminum phosphateAluminum phosphate may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved
AmineptineAmineptine may increase the stimulatory activities of Dextroamphetamine.Illicit, Withdrawn
AmiodaroneThe metabolism of Dextroamphetamine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideAmisulpride may decrease the stimulatory activities of Dextroamphetamine.Approved, Investigational
AmitriptylineAmitriptyline may increase the stimulatory activities of Dextroamphetamine.Approved
Ammonium chlorideThe serum concentration of Dextroamphetamine can be decreased when it is combined with Ammonium chloride.Approved, Vet Approved
AmperozideAmperozide may decrease the stimulatory activities of Dextroamphetamine.Experimental
AntazolineDextroamphetamine may decrease the sedative activities of Antazoline.Approved
AripiprazoleAripiprazole may decrease the stimulatory activities of Dextroamphetamine.Approved, Investigational
ArtemetherThe metabolism of Dextroamphetamine can be decreased when combined with Artemether.Approved
AsenapineAsenapine may decrease the stimulatory activities of Dextroamphetamine.Approved
AstemizoleDextroamphetamine may decrease the sedative activities of Astemizole.Approved, Withdrawn
AtomoxetineThe metabolism of Dextroamphetamine can be decreased when combined with Atomoxetine.Approved
AzaperoneAzaperone may decrease the stimulatory activities of Dextroamphetamine.Vet Approved
AzatadineDextroamphetamine may decrease the sedative activities of Azatadine.Approved
AzelastineDextroamphetamine may decrease the sedative activities of Azelastine.Approved
BenmoxinBenmoxin may increase the hypertensive activities of Dextroamphetamine.Withdrawn
BenperidolBenperidol may decrease the stimulatory activities of Dextroamphetamine.Investigational
BetaxololThe metabolism of Dextroamphetamine can be decreased when combined with Betaxolol.Approved
BezitramideDextroamphetamine may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BifeprunoxBifeprunox may decrease the stimulatory activities of Dextroamphetamine.Investigational
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of Dextroamphetamine.Approved
BromperidolBromperidol may decrease the stimulatory activities of Dextroamphetamine.Investigational
BrompheniramineDextroamphetamine may decrease the sedative activities of Brompheniramine.Approved
BuclizineDextroamphetamine may decrease the sedative activities of Buclizine.Approved
BuprenorphineDextroamphetamine may increase the analgesic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Dextroamphetamine can be decreased when combined with Bupropion.Approved
Butanoic AcidDextroamphetamine may decrease the sedative activities of Butanoic Acid.Experimental
ButorphanolDextroamphetamine may increase the analgesic activities of Butorphanol.Approved, Illicit, Vet Approved
Calcium carbonateCalcium carbonate may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved
CarbinoxamineDextroamphetamine may decrease the sedative activities of Carbinoxamine.Approved
CarfentanilDextroamphetamine may increase the analgesic activities of Carfentanil.Illicit, Vet Approved
CariprazineCariprazine may decrease the stimulatory activities of Dextroamphetamine.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of Dextroamphetamine.Withdrawn
CelecoxibThe metabolism of Dextroamphetamine can be decreased when combined with Celecoxib.Approved, Investigational
CetirizineDextroamphetamine may decrease the sedative activities of Cetirizine.Approved
ChloropyramineDextroamphetamine may decrease the sedative activities of Chloropyramine.Approved
ChloroquineThe metabolism of Dextroamphetamine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorphenamineDextroamphetamine may decrease the sedative activities of Chlorphenamine.Approved
ChlorphenoxamineDextroamphetamine may decrease the sedative activities of Chlorphenoxamine.Withdrawn
ChlorpromazineThe metabolism of Dextroamphetamine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Dextroamphetamine.Approved, Withdrawn
CholecalciferolThe metabolism of Dextroamphetamine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Dextroamphetamine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Dextroamphetamine can be decreased when combined with Cinacalcet.Approved
CinnarizineDextroamphetamine may decrease the sedative activities of Cinnarizine.Approved
CitalopramThe metabolism of Dextroamphetamine can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Dextroamphetamine can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Dextroamphetamine can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineThe metabolism of Dextroamphetamine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClotrimazoleThe metabolism of Dextroamphetamine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Dextroamphetamine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Dextroamphetamine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Dextroamphetamine can be decreased when combined with Cocaine.Approved, Illicit
CodeineDextroamphetamine may increase the analgesic activities of Codeine.Approved, Illicit
CyamemazineCyamemazine may decrease the stimulatory activities of Dextroamphetamine.Approved
CyclizineDextroamphetamine may decrease the sedative activities of Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may increase the stimulatory activities of Dextroamphetamine.Approved
CyproheptadineDextroamphetamine may decrease the sedative activities of Cyproheptadine.Approved
DapiprazoleDapiprazole may decrease the stimulatory activities of Dextroamphetamine.Approved
DarifenacinThe metabolism of Dextroamphetamine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Dextroamphetamine can be increased when it is combined with Darunavir.Approved
DelavirdineThe metabolism of Dextroamphetamine can be decreased when combined with Delavirdine.Approved
DesipramineThe metabolism of Dextroamphetamine can be decreased when combined with Desipramine.Approved
DesloratadineDextroamphetamine may decrease the sedative activities of Desloratadine.Approved, Investigational
DexbrompheniramineDextroamphetamine may decrease the sedative activities of Dexbrompheniramine.Approved
Dexchlorpheniramine maleateDextroamphetamine may decrease the sedative activities of Dexchlorpheniramine maleate.Approved
DextromoramideDextroamphetamine may increase the analgesic activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneDextroamphetamine may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineDextroamphetamine may increase the analgesic activities of Dezocine.Approved
DiclofenamideDiclofenamide may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved
DihydrocodeineDextroamphetamine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
DihydroetorphineDextroamphetamine may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineDextroamphetamine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
DimenhydrinateDextroamphetamine may decrease the sedative activities of Dimenhydrinate.Approved
DimetindeneDextroamphetamine may decrease the sedative activities of Dimetindene.Approved
DimetotiazineDextroamphetamine may decrease the sedative activities of Dimetotiazine.Approved
DiphenhydramineThe metabolism of Dextroamphetamine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateDextroamphetamine may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DosulepinDosulepin may increase the stimulatory activities of Dextroamphetamine.Approved
DoxepinDextroamphetamine may decrease the sedative activities of Doxepin.Approved
DoxylamineDextroamphetamine may decrease the sedative activities of Doxylamine.Approved, Vet Approved
DPDPEDextroamphetamine may increase the analgesic activities of DPDPE.Investigational
DronedaroneThe metabolism of Dextroamphetamine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may decrease the stimulatory activities of Dextroamphetamine.Approved, Vet Approved
DuloxetineThe metabolism of Dextroamphetamine can be decreased when combined with Duloxetine.Approved
EbastineDextroamphetamine may decrease the sedative activities of Ebastine.Investigational
EcopipamEcopipam may decrease the stimulatory activities of Dextroamphetamine.Investigational
EliglustatThe metabolism of Dextroamphetamine can be decreased when combined with Eliglustat.Approved
EmedastineDextroamphetamine may decrease the sedative activities of Emedastine.Approved
EpinastineDextroamphetamine may decrease the sedative activities of Epinastine.Approved, Investigational
EsmirtazapineDextroamphetamine may decrease the sedative activities of Esmirtazapine.Investigational
EsomeprazoleEsomeprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
EthopropazineDextroamphetamine may decrease the sedative activities of Ethopropazine.Approved
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Dextroamphetamine.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Withdrawn
EthylmorphineDextroamphetamine may increase the analgesic activities of Ethylmorphine.Approved, Illicit
EtorphineDextroamphetamine may increase the analgesic activities of Etorphine.Illicit, Vet Approved
FamotidineDextroamphetamine may decrease the sedative activities of Famotidine.Approved
FencamfamineFencamfamine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit, Withdrawn
FentanylDextroamphetamine may increase the analgesic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dextroamphetamine.Approved
FexofenadineDextroamphetamine may decrease the sedative activities of Fexofenadine.Approved
FlunarizineDextroamphetamine may decrease the sedative activities of Flunarizine.Approved
FluoxetineThe metabolism of Dextroamphetamine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may decrease the stimulatory activities of Dextroamphetamine.Approved, Withdrawn
FluphenazineFluphenazine may decrease the stimulatory activities of Dextroamphetamine.Approved
FluspirileneFluspirilene may decrease the stimulatory activities of Dextroamphetamine.Approved
FluvoxamineThe metabolism of Dextroamphetamine can be decreased when combined with Fluvoxamine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Dextroamphetamine.Approved, Vet Approved
GuanethidineThe serum concentration of Dextroamphetamine can be decreased when it is combined with Guanethidine.Approved
HaloperidolThe metabolism of Dextroamphetamine can be decreased when combined with Haloperidol.Approved
HeroinDextroamphetamine may increase the analgesic activities of Heroin.Approved, Illicit
HexamethylenetetramineThe serum concentration of Dextroamphetamine can be decreased when it is combined with Hexamethylenetetramine.Approved, Vet Approved
HydracarbazineHydracarbazine may increase the hypertensive activities of Dextroamphetamine.Approved
HydrocodoneDextroamphetamine may increase the analgesic activities of Hydrocodone.Approved, Illicit
HydromorphoneDextroamphetamine may increase the analgesic activities of Hydromorphone.Approved, Illicit
HydroxyzineDextroamphetamine may decrease the sedative activities of Hydroxyzine.Approved
IloperidoneIloperidone may decrease the stimulatory activities of Dextroamphetamine.Approved
ImipramineThe metabolism of Dextroamphetamine can be decreased when combined with Imipramine.Approved
IndinavirThe metabolism of Dextroamphetamine can be decreased when combined with Indinavir.Approved
Ioflupane I-123Dextroamphetamine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IproclozideIproclozide may increase the hypertensive activities of Dextroamphetamine.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Dextroamphetamine.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Dextroamphetamine.Approved
IsoniazidThe metabolism of Dextroamphetamine can be decreased when combined with Isoniazid.Approved
IsothipendylDextroamphetamine may decrease the sedative activities of Isothipendyl.Approved
Kct 0809Dextroamphetamine may decrease the sedative activities of Kct 0809.Investigational
KetobemidoneDextroamphetamine may increase the analgesic activities of Ketobemidone.Approved
KetoconazoleThe metabolism of Dextroamphetamine can be decreased when combined with Ketoconazole.Approved, Investigational
KetotifenDextroamphetamine may decrease the sedative activities of Ketotifen.Approved
L-Glutamic AcidThe serum concentration of Dextroamphetamine can be decreased when it is combined with L-Glutamic Acid.Nutraceutical
LansoprazoleLansoprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
LevocabastineDextroamphetamine may decrease the sedative activities of Levocabastine.Approved
LevocetirizineDextroamphetamine may decrease the sedative activities of Levocetirizine.Approved
Levomethadyl AcetateDextroamphetamine may increase the analgesic activities of Levomethadyl Acetate.Approved
LevorphanolDextroamphetamine may increase the analgesic activities of Levorphanol.Approved
LithiumLithium may decrease the stimulatory activities of Dextroamphetamine.Approved
LodoxamideDextroamphetamine may decrease the sedative activities of Lodoxamide.Approved
LofentanilDextroamphetamine may increase the analgesic activities of Lofentanil.Illicit
LopinavirThe metabolism of Dextroamphetamine can be decreased when combined with Lopinavir.Approved
LoratadineDextroamphetamine may decrease the sedative activities of Loratadine.Approved
LorcaserinThe metabolism of Dextroamphetamine can be decreased when combined with Lorcaserin.Approved
LoxapineLoxapine may decrease the stimulatory activities of Dextroamphetamine.Approved
LumefantrineThe metabolism of Dextroamphetamine can be decreased when combined with Lumefantrine.Approved
LurasidoneLurasidone may decrease the stimulatory activities of Dextroamphetamine.Approved
MagaldrateMagaldrate may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Withdrawn
Magnesium carbonateMagnesium carbonate may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved
Magnesium hydroxideMagnesium hydroxide may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved
Magnesium oxideMagnesium oxide may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved
MebanazineMebanazine may increase the hypertensive activities of Dextroamphetamine.Withdrawn
MeclizineDextroamphetamine may decrease the sedative activities of Meclizine.Approved
MelperoneMelperone may decrease the stimulatory activities of Dextroamphetamine.Approved
MepyramineDextroamphetamine may decrease the sedative activities of Mepyramine.Approved, Vet Approved
MequitazineDextroamphetamine may decrease the sedative activities of Mequitazine.Approved
MesoridazineMesoridazine may decrease the stimulatory activities of Dextroamphetamine.Approved
MethadoneThe metabolism of Dextroamphetamine can be decreased when combined with Methadone.Approved
Methadyl AcetateDextroamphetamine may increase the analgesic activities of Methadyl Acetate.Approved, Illicit
MethapyrileneDextroamphetamine may decrease the sedative activities of Methapyrilene.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved
MethotrimeprazineThe metabolism of Dextroamphetamine can be decreased when combined with Methotrimeprazine.Approved
Methylene blueMethylene blue may increase the hypertensive activities of Dextroamphetamine.Investigational
MetiamideDextroamphetamine may decrease the sedative activities of Metiamide.Experimental
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Dextroamphetamine.Approved, Investigational
MianserinDextroamphetamine may decrease the sedative activities of Mianserin.Approved
MinaprineMinaprine may increase the hypertensive activities of Dextroamphetamine.Approved
MirabegronThe metabolism of Dextroamphetamine can be decreased when combined with Mirabegron.Approved
MirtazapineDextroamphetamine may decrease the sedative activities of Mirtazapine.Approved
MizolastineDextroamphetamine may decrease the sedative activities of Mizolastine.Investigational
MoclobemideMoclobemide may increase the hypertensive activities of Dextroamphetamine.Approved
MolindoneMolindone may decrease the stimulatory activities of Dextroamphetamine.Approved
MorphineDextroamphetamine may increase the analgesic activities of Morphine.Approved, Investigational
NalbuphineDextroamphetamine may increase the analgesic activities of Nalbuphine.Approved
NevirapineThe metabolism of Dextroamphetamine can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypertensive activities of Dextroamphetamine.Withdrawn
NicardipineThe metabolism of Dextroamphetamine can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Dextroamphetamine can be decreased when combined with Nilotinib.Approved, Investigational
NizatidineDextroamphetamine may decrease the sedative activities of Nizatidine.Approved
NormethadoneDextroamphetamine may increase the analgesic activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the stimulatory activities of Dextroamphetamine.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Dextroamphetamine.Withdrawn
OlanzapineOlanzapine may decrease the stimulatory activities of Dextroamphetamine.Approved, Investigational
OlopatadineDextroamphetamine may decrease the sedative activities of Olopatadine.Approved
OmeprazoleOmeprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational, Vet Approved
OndansetronOndansetron may decrease the stimulatory activities of Dextroamphetamine.Approved
OpipramolOpipramol may increase the stimulatory activities of Dextroamphetamine.Investigational
OpiumDextroamphetamine may increase the analgesic activities of Opium.Approved, Illicit
OsanetantOsanetant may decrease the stimulatory activities of Dextroamphetamine.Investigational
OxycodoneDextroamphetamine may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
OxymorphoneDextroamphetamine may increase the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
PaliperidonePaliperidone may decrease the stimulatory activities of Dextroamphetamine.Approved
PanobinostatThe serum concentration of Dextroamphetamine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazolePantoprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
PargylinePargyline may increase the hypertensive activities of Dextroamphetamine.Approved
ParoxetineThe metabolism of Dextroamphetamine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Dextroamphetamine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PemirolastDextroamphetamine may decrease the sedative activities of Pemirolast.Approved
PentazocineDextroamphetamine may increase the analgesic activities of Pentazocine.Approved, Vet Approved
PerazinePerazine may decrease the stimulatory activities of Dextroamphetamine.Investigational
PerospironePerospirone may decrease the stimulatory activities of Dextroamphetamine.Approved
PerphenazinePerphenazine may decrease the stimulatory activities of Dextroamphetamine.Approved
PethidineDextroamphetamine may increase the analgesic activities of Pethidine.Approved
PhenelzinePhenelzine may increase the hypertensive activities of Dextroamphetamine.Approved
PhenindamineDextroamphetamine may decrease the sedative activities of Phenindamine.Approved
PheniprazinePheniprazine may increase the hypertensive activities of Dextroamphetamine.Withdrawn
PheniramineDextroamphetamine may decrease the sedative activities of Pheniramine.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Dextroamphetamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Dextroamphetamine.Withdrawn
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Dextroamphetamine.Approved, Vet Approved
PimozidePimozide may decrease the stimulatory activities of Dextroamphetamine.Approved
PipamperonePipamperone may decrease the stimulatory activities of Dextroamphetamine.Approved
PipotiazinePipotiazine may decrease the stimulatory activities of Dextroamphetamine.Approved
PiritramideDextroamphetamine may increase the analgesic activities of Piritramide.Investigational
PirlindolePirlindole may increase the hypertensive activities of Dextroamphetamine.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Dextroamphetamine.Withdrawn
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Dextroamphetamine.Approved, Vet Approved
PromazineThe metabolism of Dextroamphetamine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineDextroamphetamine may decrease the sedative activities of Promethazine.Approved
PropericiazinePropericiazine may decrease the stimulatory activities of Dextroamphetamine.Approved
ProthipendylProthipendyl may decrease the stimulatory activities of Dextroamphetamine.Investigational
ProtriptylineProtriptyline may increase the stimulatory activities of Dextroamphetamine.Approved
QuetiapineQuetiapine may decrease the stimulatory activities of Dextroamphetamine.Approved
QuinidineThe metabolism of Dextroamphetamine can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Dextroamphetamine can be decreased when combined with Quinine.Approved
RabeprazoleRabeprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
RacloprideRaclopride may decrease the stimulatory activities of Dextroamphetamine.Investigational
RanitidineDextroamphetamine may decrease the sedative activities of Ranitidine.Approved
RanolazineThe metabolism of Dextroamphetamine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypertensive activities of Dextroamphetamine.Approved
RemifentanilDextroamphetamine may increase the analgesic activities of Remifentanil.Approved
RemoxiprideRemoxipride may decrease the stimulatory activities of Dextroamphetamine.Approved, Withdrawn
ReserpineReserpine may decrease the stimulatory activities of Dextroamphetamine.Approved
RisperidoneRisperidone may decrease the stimulatory activities of Dextroamphetamine.Approved, Investigational
RitanserinRitanserin may decrease the stimulatory activities of Dextroamphetamine.Investigational
RitonavirThe metabolism of Dextroamphetamine can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Dextroamphetamine can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Dextroamphetamine can be decreased when combined with Ropinirole.Approved, Investigational
Roxatidine acetateDextroamphetamine may decrease the sedative activities of Roxatidine acetate.Approved
SafrazineSafrazine may increase the hypertensive activities of Dextroamphetamine.Withdrawn
SelegilineSelegiline may increase the hypertensive activities of Dextroamphetamine.Approved, Investigational, Vet Approved
SertindoleSertindole may decrease the stimulatory activities of Dextroamphetamine.Approved, Withdrawn
SertralineThe metabolism of Dextroamphetamine can be decreased when combined with Sertraline.Approved
Spaglumic AcidDextroamphetamine may decrease the sedative activities of Spaglumic Acid.Approved
StiripentolThe metabolism of Dextroamphetamine can be decreased when combined with Stiripentol.Approved
SufentanilDextroamphetamine may increase the analgesic activities of Sufentanil.Approved, Investigational
SulpirideSulpiride may decrease the stimulatory activities of Dextroamphetamine.Approved
TAK-390MRTAK-390MR can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Investigational
TapentadolDextroamphetamine may increase the analgesic activities of Tapentadol.Approved
TerbinafineThe metabolism of Dextroamphetamine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineDextroamphetamine may decrease the sedative activities of Terfenadine.Withdrawn
TesmilifeneDextroamphetamine may decrease the sedative activities of Tesmilifene.Investigational
ThioproperazineThioproperazine may decrease the stimulatory activities of Dextroamphetamine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Dextroamphetamine.Approved
ThiothixeneThiothixene may decrease the stimulatory activities of Dextroamphetamine.Approved
ThonzylamineDextroamphetamine may decrease the sedative activities of Thonzylamine.Approved
TianeptineTianeptine may increase the stimulatory activities of Dextroamphetamine.Approved
TiaprideTiapride may decrease the stimulatory activities of Dextroamphetamine.Investigational
TiclopidineThe metabolism of Dextroamphetamine can be decreased when combined with Ticlopidine.Approved
TipranavirThe metabolism of Dextroamphetamine can be decreased when combined with Tipranavir.Approved, Investigational
ToloxatoneToloxatone may increase the hypertensive activities of Dextroamphetamine.Approved
TramadolDextroamphetamine may increase the analgesic activities of Tramadol.Approved, Investigational
TranilastDextroamphetamine may decrease the sedative activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Dextroamphetamine.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Dextroamphetamine.Approved
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Dextroamphetamine.Approved
TriflupromazineTriflupromazine may decrease the stimulatory activities of Dextroamphetamine.Approved, Vet Approved
TrimipramineTrimipramine may increase the stimulatory activities of Dextroamphetamine.Approved
TripelennamineDextroamphetamine may decrease the sedative activities of Tripelennamine.Approved, Vet Approved
TriprolidineDextroamphetamine may decrease the sedative activities of Triprolidine.Approved
VenlafaxineThe metabolism of Dextroamphetamine can be decreased when combined with Venlafaxine.Approved
Vitamin CThe serum concentration of Dextroamphetamine can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
ZiprasidoneThe metabolism of Dextroamphetamine can be decreased when combined with Ziprasidone.Approved
ZotepineZotepine may decrease the stimulatory activities of Dextroamphetamine.Approved
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of Dextroamphetamine.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Nabenhauer, F.P.; US. Patent 2,276,508; March 17,1942; assigned to Smith, Kline & French
Laboratories.

General References
  1. Yamada H, Baba T, Hirata Y, Oguri K, Yoshimura H: Studies on N-demethylation of methamphetamine by liver microsomes of guinea-pigs and rats: the role of flavin-containing mono-oxygenase and cytochrome P-450 systems. Xenobiotica. 1984 Nov;14(11):861-6. [PubMed:6506758 ]
  2. Warneke L: Psychostimulants in psychiatry. Can J Psychiatry. 1990 Feb;35(1):3-10. [PubMed:2180548 ]
  3. Wagner GJ, Rabkin R: Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2000 Jun;61(6):436-40. [PubMed:10901342 ]
  4. Martinsson L, Yang X, Beck O, Wahlgren NG, Eksborg S: Pharmacokinetics of dexamphetamine in acute stroke. Clin Neuropharmacol. 2003 Sep-Oct;26(5):270-6. [PubMed:14520168 ]
  5. Butefisch CM, Davis BC, Sawaki L, Waldvogel D, Classen J, Kopylev L, Cohen LG: Modulation of use-dependent plasticity by d-amphetamine. Ann Neurol. 2002 Jan;51(1):59-68. [PubMed:11782985 ]
External Links
ATC CodesN06BA02
AHFS Codes
  • 28:20.04
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9972
Blood Brain Barrier+0.9565
Caco-2 permeable+0.8395
P-glycoprotein substrateNon-substrate0.7379
P-glycoprotein inhibitor INon-inhibitor0.9519
P-glycoprotein inhibitor IINon-inhibitor0.9859
Renal organic cation transporterNon-inhibitor0.8002
CYP450 2C9 substrateNon-substrate0.8114
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.795
CYP450 1A2 substrateNon-inhibitor0.5697
CYP450 2C9 inhibitorNon-inhibitor0.9313
CYP450 2D6 inhibitorInhibitor0.657
CYP450 2C19 inhibitorNon-inhibitor0.8445
CYP450 3A4 inhibitorNon-inhibitor0.8709
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8732
Ames testNon AMES toxic0.93
CarcinogenicityNon-carcinogens0.6869
BiodegradationNot ready biodegradable0.6575
Rat acute toxicity3.2491 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9452
hERG inhibition (predictor II)Non-inhibitor0.9231
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsule, extended releaseOral10 mg
Capsule, extended releaseOral15 mg
TabletOral5 mg
CapsuleOral
TabletOral
Capsule, extended releaseOral
TabletOral10 mg/1
TabletOral5 mg/1
Capsule, extended releaseOral10 mg/1
Capsule, extended releaseOral15 mg/1
Capsule, extended releaseOral5 mg/1
LiquidOral5 mg/5mL
SolutionOral5 mg/5mL
TabletOral15 mg/1
TabletOral2.5 mg/1
TabletOral20 mg/1
TabletOral30 mg/1
TabletOral7.5 mg/1
Prices
Unit descriptionCostUnit
D-amphetamine sulfate powder900.0USD g
Desoxyn 5 mg tablet5.1USD tablet
Dexedrine 15 mg 24 Hour Capsule4.22USD capsule
Dextroamphetamine Sulfate CR 15 mg 24 Hour Capsule3.47USD capsule
Dexedrine 10 mg 24 Hour Capsule3.23USD capsule
Dexedrine 5 mg 24 Hour Capsule3.0USD capsule
Dextroamphetamine Sulfate CR 10 mg 24 Hour Capsule2.96USD capsule
Dexedrine spansule 15 mg2.45USD each
Dextroamphetamine Sulfate CR 5 mg 24 Hour Capsule2.06USD capsule
Dexedrine spansule 10 mg1.91USD each
Dexedrine spansule 5 mg1.91USD each
Dexedrine 15 mg Sustained-Release Capsule1.08USD capsule
Dextroamphetamine Sulfate 10 mg tablet0.92USD tablet
Dexedrine 10 mg Sustained-Release Capsule0.89USD capsule
Dextroamphetamine Sulfate 5 mg tablet0.65USD tablet
Dexedrine 5 mg Tablet0.62USD tablet
Dextroamphetamine 10 mg tablet0.56USD tablet
Dextrostat 10 mg tablet0.48USD tablet
Dextroamphetamine 5 mg tablet0.28USD tablet
Dextrostat 5 mg tablet0.25USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6322819 Yes1999-04-212019-04-21Us
US6384020 Yes2001-01-062021-01-06Us
US6605300 Yes1999-04-212019-04-21Us
USRE41148 Yes1999-04-212019-04-21Us
USRE42096 Yes1999-04-212019-04-21Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point< 25 °CPhysProp
boiling point203 °CPhysProp
logP1.76SANGSTER (1994); similar isomer
pKa9.9SANGSTER (1994); similar isomer
Predicted Properties
PropertyValueSource
Water Solubility1.74 mg/mLALOGPS
logP1.85ALOGPS
logP1.8ChemAxon
logS-1.9ALOGPS
pKa (Strongest Basic)10.01ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.02 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity43.71 m3·mol-1ChemAxon
Polarizability16.08 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (6.85 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0006-9000000000-f40d32a5bced4783345aView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenethylamines
Direct ParentAmphetamines and derivatives
Alternative Parents
Substituents
  • Amphetamine or derivatives
  • Phenylpropane
  • Aralkylamine
  • Hydrocarbon derivative
  • Primary amine
  • Organonitrogen compound
  • Primary aliphatic amine
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Involved in the ATP-dependent vesicular transport of biogenic amine neurotransmitters. Pumps cytosolic monoamines including dopamine, norepinephrine, serotonin, and histamine into synaptic vesicles. Requisite for vesicular amine storage prior to secretion via exocytosis.
Gene Name:
SLC18A2
Uniprot ID:
Q05940
Molecular Weight:
55712.075 Da
References
  1. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A: Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci. 1995 May;15(5 Pt 2):4102-8. [PubMed:7751968 ]
  2. Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005 Apr;75(6):406-33. [PubMed:15955613 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
negative modulator
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Dlugos A, Freitag C, Hohoff C, McDonald J, Cook EH, Deckert J, de Wit H: Norepinephrine transporter gene variation modulates acute response to D-amphetamine. Biol Psychiatry. 2007 Jun 1;61(11):1296-305. Epub 2007 Jan 17. [PubMed:17239355 ]
  2. Dlugos AM, Hamidovic A, Palmer AA, de Wit H: Further evidence of association between amphetamine response and SLC6A2 gene variants. Psychopharmacology (Berl). 2009 Oct;206(3):501-11. doi: 10.1007/s00213-009-1628-y. [PubMed:19727679 ]
  3. Burnette WB, Bailey MD, Kukoyi S, Blakely RD, Trowbridge CG, Justice JB Jr: Human norepinephrine transporter kinetics using rotating disk electrode voltammetry. Anal Chem. 1996 Sep 1;68(17):2932-8. [PubMed:8794928 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
negative modulator
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Zhen J, Chen N, Reith ME: Differences in interactions with the dopamine transporter as revealed by diminishment of Na(+) gradient and membrane potential: dopamine versus other substrates. Neuropharmacology. 2005 Nov;49(6):769-79. Epub 2005 Aug 24. [PubMed:16122767 ]
  2. Kuczenski R, Segal DS, Cho AK, Melega W: Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci. 1995 Feb;15(2):1308-17. [PubMed:7869099 ]
  3. Rothman RB, Dersch CM, Ananthan S, Partilla JS: Studies of the biogenic amine transporters. 13. Identification of "agonist" and "antagonist" allosteric modulators of amphetamine-induced dopamine release. J Pharmacol Exp Ther. 2009 May;329(2):718-28. doi: 10.1124/jpet.108.149088. Epub 2009 Feb 24. [PubMed:19244097 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Trace-amine receptor activity
Specific Function:
Receptor for trace amines, including beta-phenylethylamine (b-PEA), p-tyramine (p-TYR), octopamine and tryptamine, with highest affinity for b-PEA and p-TYR. Unresponsive to classical biogenic amines, such as epinephrine and histamine and only partially activated by dopamine and serotonine. Trace amines are biogenic amines present in very low levels in mammalian tissues. Although some trace ami...
Gene Name:
TAAR1
Uniprot ID:
Q96RJ0
Molecular Weight:
39091.34 Da
References
  1. Reese EA, Bunzow JR, Arttamangkul S, Sonders MS, Grandy DK: Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine. J Pharmacol Exp Ther. 2007 Apr;321(1):178-86. Epub 2007 Jan 11. [PubMed:17218486 ]
  2. Xie Z, Westmoreland SV, Bahn ME, Chen GL, Yang H, Vallender EJ, Yao WD, Madras BK, Miller GM: Rhesus monkey trace amine-associated receptor 1 signaling: enhancement by monoamine transporters and attenuation by the D2 autoreceptor in vitro. J Pharmacol Exp Ther. 2007 Apr;321(1):116-27. Epub 2007 Jan 18. [PubMed:17234900 ]
  3. Wolinsky TD, Swanson CJ, Smith KE, Zhong H, Borowsky B, Seeman P, Branchek T, Gerald CP: The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav. 2007 Oct;6(7):628-39. Epub 2006 Dec 21. [PubMed:17212650 ]
  4. Xie Z, Miller GM: Trace amine-associated receptor 1 is a modulator of the dopamine transporter. J Pharmacol Exp Ther. 2007 Apr;321(1):128-36. Epub 2007 Jan 18. [PubMed:17234899 ]
  5. Miller GM, Verrico CD, Jassen A, Konar M, Yang H, Panas H, Bahn M, Johnson R, Madras BK: Primate trace amine receptor 1 modulation by the dopamine transporter. J Pharmacol Exp Ther. 2005 Jun;313(3):983-94. Epub 2005 Mar 11. [PubMed:15764732 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on August 29, 2007 08:50 / Updated on December 05, 2016 03:58